Partnership revenue fluctuations to continue through FY26
Management expects inventory phasing and frozen periods to cause quarterly volatility, with stabilization by end of FY26.
SANOFIINDIA / guidance tracker
Keep management guidance in view.
Sanofi India · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
Diabetes segment to sustain double-digit growth
Driven by insulin portfolio (Toujeo, Soliqua) and expansion in public sector, though market dynamics remain volatile.
No new product launches in FY26
Focus remains on maximizing current portfolio (Soliqua, Toujeo) and real-world evidence publications.